title: [Biological treatment of rheumatic diseases].
abstract: During recent two decades the progress in the understanding of the pathogenesis of the autoimmune diseases have led to new treatment targets, whose achievement claims new therapeutic advancings. Biological drugs complete or replace conventional immunosuppressive therapies in the treatment of autoimmune diseases. In the treatment of rheumatic diseases are currently used TNFalpha inhibitors and blockade of the IL-1, in phase of clinical trials or actual registration are agents blocking IL-6, the antibodies against B cell and inhibition of activation of T-cells by costimulating blockade with CTLA4Ig. In the Czech Republic are for treating of rheumatic diseases approved TNF blocking drugs. Treatment with this drugs is centred in biological therapy centres and patients are enroled into Registry of patients treated with anti TNFalpha drugs (ATTRA), which enable longterm observation of efficacy and toxicity.
authors.affiliation: II. interní klinika Lékarské fakulty MU a FN u sv. Anny, Brno. leona.prochazkova@fnusa.cz
authors.forename: L
authors.initials: L
authors.lastname: Procházková
authors.forename: J
authors.initials: J
authors.lastname: Böhmová
authors.forename: M
authors.initials: M
authors.lastname: Soucek
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha